These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 24018887)

  • 1. Molecular signatures in urologic tumors.
    Larkin S; Kyprianou N
    Int J Mol Sci; 2013 Sep; 14(9):18421-36. PubMed ID: 24018887
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Liquid biopsy: a step forward towards precision medicine in urologic malignancies.
    Di Meo A; Bartlett J; Cheng Y; Pasic MD; Yousef GM
    Mol Cancer; 2017 Apr; 16(1):80. PubMed ID: 28410618
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [MicroRNAs as potential noninvasive markers in the diagnosis of urological malignancies].
    Gilyazova IR; Klimentova EA; Pavlov VN; Khusnutdinova EK
    Urologiia; 2016 Apr; (2):96-102. PubMed ID: 28247670
    [TBL] [Abstract][Full Text] [Related]  

  • 4. C-reactive protein as a biomarker for urological cancers.
    Saito K; Kihara K
    Nat Rev Urol; 2011 Oct; 8(12):659-66. PubMed ID: 22025173
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epigenetic biomarkers in the blood of patients with urological malignancies.
    Ellinger J; Müller SC; Dietrich D
    Expert Rev Mol Diagn; 2015 Apr; 15(4):505-16. PubMed ID: 25719388
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Emergence of Precision Urologic Oncology: A Collaborative Review on Biomarker-driven Therapeutics.
    Barbieri CE; Chinnaiyan AM; Lerner SP; Swanton C; Rubin MA
    Eur Urol; 2017 Feb; 71(2):237-246. PubMed ID: 27567210
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biomarker development in the context of urologic cancers.
    Kelloff GJ; Sigman CC; Scher HI
    Urol Oncol; 2015 Jun; 33(6):295-301. PubMed ID: 25746942
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Extracellular Vesicles and Their Role in Urologic Malignancies.
    Junker K; Heinzelmann J; Beckham C; Ochiya T; Jenster G
    Eur Urol; 2016 Aug; 70(2):323-31. PubMed ID: 26924769
    [TBL] [Abstract][Full Text] [Related]  

  • 9. C-reactive protein in bladder cancer: where do we stand?
    Gakis G; Stenzl A
    Nat Rev Urol; 2013 Mar; 10(3):182. PubMed ID: 23381597
    [No Abstract]   [Full Text] [Related]  

  • 10. Epigenetic biomarkers in urological tumors: A systematic review.
    Jerónimo C; Henrique R
    Cancer Lett; 2014 Jan; 342(2):264-74. PubMed ID: 22198482
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Urine microRNAs as potential noninvasive biomarkers in urologic cancers.
    Mlcochova H; Hezova R; Stanik M; Slaby O
    Urol Oncol; 2014 Jan; 32(1):41.e1-9. PubMed ID: 24035473
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Emerging critical role of molecular testing in diagnostic genitourinary pathology.
    Netto GJ; Cheng L
    Arch Pathol Lab Med; 2012 Apr; 136(4):372-90. PubMed ID: 22458900
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Author's reply: CRP kinetics could be prognostic predictors in urothelial cancer.
    Saito K; Kihara K
    Nat Rev Urol; 2013 Mar; 10(3):182. PubMed ID: 23381595
    [No Abstract]   [Full Text] [Related]  

  • 14. Crucial Roles of microRNA-Mediated Autophagy in Urologic Malignancies.
    Shen M; Li X; Qian B; Wang Q; Lin S; Wu W; Zhu S; Zhu R; Zhao S
    Int J Biol Sci; 2021; 17(13):3356-3368. PubMed ID: 34512152
    [TBL] [Abstract][Full Text] [Related]  

  • 15. P63 immunoreactivity distinguishes upper urinary tract transitional-cell carcinoma and renal-cell carcinoma even in poorly differentiated tumors.
    Langner C; Ratschek M; Tsybrovskyy O; Schips L; Zigeuner R
    J Histochem Cytochem; 2003 Aug; 51(8):1097-9. PubMed ID: 12871991
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tissue microarrays: applications in urological cancer research.
    Merseburger AS; Anastasiadis AG; Hennenlotter J; Schilling D; Simon P; Machtens SA; Serth J; Stenzl A; Kuczyk MA
    World J Urol; 2006 Nov; 24(5):579-84. PubMed ID: 16896596
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of molecular targets in urologic oncology.
    Evans CP
    World J Urol; 2009 Feb; 27(1):3-8. PubMed ID: 19002690
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potential biomarkers and risk assessment models to enhance the tumor-node-metastasis (TNM) staging classification of urologic cancers.
    Darrell CM; Montironi R; Paner GP
    Expert Rev Mol Diagn; 2020 Sep; 20(9):921-932. PubMed ID: 32876523
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nanomedicine for urologic cancers: diagnosis and management.
    Li C; Zeng X; Qiu S; Gu Y; Zhang Y
    Semin Cancer Biol; 2022 Nov; 86(Pt 2):463-475. PubMed ID: 35660001
    [TBL] [Abstract][Full Text] [Related]  

  • 20. How can biomarkers assist the prognosis of urologic malignancies?
    Falzarano SM; Feely MM
    Expert Rev Mol Diagn; 2020 Feb; 20(2):131-133. PubMed ID: 31495243
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.